Healthcare, Pharma & Life Sciences

eMed, Female Quotient Partner to Close $1 Trillion Women's Health Gap

Miami – September 29, 2026 -- eMed, a digital healthcare company, and The Female Quotient, a global media and experiences firm reaching over 8 million leaders across 30 industries, have announced a strategic partnership targeting a $1 trillion annual opportunity in the global economy by 2040 tied to closing the women's health gap.

Partnership launches at New York summit on October 14

The collaboration will officially debut at the FQ Health Summit in New York City, where executives will discuss innovation to address disparities in women's healthcare access. Chloe Ferro and Olivia Ferro, founders of sheMed, will join the discussion to share perspectives on personalized care.

PBS Biotech Embeds Rockwell Automation Tech in Cell Therapy Bioreactor

Image
PBS Biotech Embeds Rockwell Automation Tech in Cell Therapy Bioreactor

Milwaukee – September 29, 2026 -- PBS Biotech has embedded Rockwell Automation technology into its MiniPRO multi-parallel bioreactor platform, a system with up to 24 independently controlled bioreactors designed to speed cell therapy process development and reduce risk during scale-up to commercial manufacturing.

Platform integrates FactoryTalk software with PlantPAx distributed control

The MiniPRO uses Rockwell's FactoryTalk software and Process Library to deliver real-time process control within an automation environment that can integrate directly into a larger PlantPAx distributed control system used to run an entire cell-therapy facility. Rockwell Automation, headquartered in Milwaukee and employing roughly 26,000 people across more than 100 countries as of fiscal year 2025, positions the collaboration as a way to standardize automation across development and GMP manufacturing stages.

Thyme Companies Names Flatiron Health Ex-CEO Starrett to Lead New Ventures

Image
Thyme Companies Names Flatiron Health Ex-CEO Starrett to Lead New Ventures

Nashville, Tenn. – – September 29, 2026 -- Thyme Companies has appointed Carolyn Starrett as executive vice president of new ventures, tasking her with identifying and scaling new businesses beyond its existing Thyme Care platform. Starrett reports directly to Executive Chairman Robin Shah, marking her second collaboration with him after their tenure together at Flatiron Health.

Starrett brings a decade of oncology data leadership from Flatiron Health

Starrett joined Flatiron Health in 2016 alongside Thyme's founders and served as its Chief Executive Officer from 2021 to 2025. Under her leadership, Flatiron's real-world evidence platform expanded from roughly 400,000 to more than 5.5 million patient records. Its OncoEMR platform grew to serve more than 4,500 oncology providers nationwide, while the company extended research operations into the United Kingdom, Germany and Japan.

Jack & Jill Foundation Marks 20 Years of Oncologist-Prescribed Family Trips

Atlanta – September 29, 2026 -- The Jack & Jill Late Stage Cancer Foundation (JAJF) has completed 20 years of funding fully-paid family trips for parents with terminal cancer diagnoses, a model now formally prescribed by oncologists across the United States as part of patient treatment protocols.

Foundation traces origin to a 2006 family diagnosis

Jon Albert founded JAJF in 2006 after his wife, Jill, was diagnosed with Stage IV metastatic breast cancer. Jill died two weeks after the foundation's launch, but the organization she inspired has since delivered what it calls WOW! Experiences to thousands of children and parents nationwide.

BioFuture 2026 Gathers 100+ Speakers to Tackle Biopharma AI, Funding, Policy

New York City – – September 29, 2026 -- Demy-Colton has released the agenda for BioFuture 2026, a two-day conference set for October 27–28 at Cure, 345 Park Avenue South, drawing more than 100 speakers and over 50 presenting companies from biopharma, investment, technology and policy sectors.

Conference agenda spans AI, oncology, biotech financing and global drug development

Speakers include representatives from Johnson & Johnson, Regeneron Pharmaceuticals, Schrödinger, Piper Sandler and Mizuho Securities. Sponsors backing the event include Regeneron Pharmaceuticals, Russo Partners, WuXi AppTec, Blue Matter, Cure, Evotec, Ipsen, Thermo Fisher Scientific, Big4Bio, HMA Consulting, Withum and Hogan Lovells Cadwalader.

Truven Launches AI Tool Cutting Data Feasibility Checks to Minutes

Image
Truven Launches AI Tool Cutting Data Feasibility Checks to Minutes

Ann Arbor – September 29, 2026 -- Truven has launched MarketScan Snapshot, an AI-powered search capability that compresses what the company says can be days or weeks of cohort feasibility research into a process taking minutes.

Snapshot lets researchers query 300 million cumulative patient lives in plain language

The tool allows users to run patient-count requests against MarketScan Research Databases using everyday language, eliminating the need to specify medical codes or possess programming skills. MarketScan's underlying dataset includes more than 300 million cumulative lives, 95 million active lives, 99% claims completeness, and data access dating back to 1995 across commercial, Medicare and Medicaid populations.

Survey: 79% of Cardiac Patients Want Home-Based Rehab, But Coverage Is Key

Campbell, Calif. – September 29, 2026 -- Vivalink, a digital healthcare solutions provider, published survey data showing 79% of more than 150 U.S. adults with cardiac conditions would participate in a home-based cardiac rehabilitation program if recommended by a provider.

Patients favor hybrid or home-based rehab over clinic visits

When given a choice, 68% of respondents said they would prefer a primarily home-based or hybrid rehabilitation approach over traditional in-clinic programs.

Insurance coverage ranks as the top barrier to participation

Fifty-eight percent of respondents ranked insurance coverage as their top consideration for participating in home-based care. Sixty percent said they would not pay out of pocket for such a program, while 87% said confirmed insurance coverage would increase their likelihood of participating.

120/80 Health Group Posts Eighth Straight Year of Record Growth

Image
120/80 Health Group Posts Eighth Straight Year of Record Growth

New York – September 29, 2026 -- 120/80 Health Group has logged its eighth consecutive year of record growth, fueled by new client wins and deepening relationships across healthcare and life sciences.

Top-10 biopharma and diagnostic firms sign on for AI-driven work

The firm added multiple category-leading clients in 2026 and began working with several top-10 global biopharmaceutical and diagnostic companies applying AI to drug, test and device development. The agency has shifted from brand-awareness communications for early-stage digital health startups to a strategic consultancy serving businesses from pre-Series A through publicly traded companies.

Massage Envy Opens $100,000 Grant Round, Lifts AMTA Funding to $550,000

Scottsdale, Ariz. – September 29, 2026 -- The American Massage Therapy Association (AMTA) will open applications October 1 for its ninth round of massage school grants funded by Massage Envy, offering ten $10,000 awards totaling $100,000. The fall cycle brings Massage Envy's cumulative funding of the program to $550,000.

Massage Envy doubles annual grant capacity in 2026

The program now distributes 10 grants per cycle in both spring and fall, up from five per cycle in prior years, effectively doubling annual grant availability for accredited massage schools.

Accredited schools can apply through October 31

Eligible massage schools must submit an online application via AMTA detailing how grant funds would support school programs and students. The application window runs October 1–31, 2026.

Acurx Enrolls First Patient in PATHFINDER Trial for Recurrent C. diff

Staten Island, N.Y. – September 29, 2026 -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has enrolled the first patient in its PATHFINDER clinical trial evaluating ibezapolstat in patients with multiply-recurrent Clostridioides difficile infection (rCDI), a condition affecting up to 40% of patients treated with vancomycin after multiple prior episodes.

Fully funded pilot trial targets approximately 20 patients with severe recurrence history

The Phase 2 PATHFINDER study is a multicenter, open-label, single-arm trial enrolling patients who have experienced at least three CDI episodes within the past 12 months. Participants receive ibezapolstat for 14 days, with assessments for Clinical Cure at Day 16, Sustained Clinical Cure at Day 42, and recurrence rates tracked through Week 24.